Toboroz
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
NCT06401330· 3. fázis· Children's Oncology Group· Forrás
Contact: Jill A. Salo (principal investigator)
Toboroz
Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma
NCT06647953· 3. fázis· Children's Oncology Group· Forrás
Contact: Jill A. Salo (principal investigator)
Toboroz
Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma
NCT06533748· 2. fázis· St. Jude Children's Research Hospital· Forrás
Contact: Ashraf Mohamed, MD
Toboroz
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
NCT06390319· 2. fázis· St. Jude Children's Research Hospital· Forrás
Contact: Ashraf Mohamed, MD
Toboroz
Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
NCT06289673· 4. fázis· St. Jude Children's Research Hospital· Forrás
Contact: Ashraf Mohamed, MD
Toboroz
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
NCT06172296· 3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Jill A. Salo (principal investigator)
Fut, nem toboroz
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
NCT05602194· 3. fázis· Children's Oncology Group· Forrás
Toboroz
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
NCT05675410· 3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Jill A. Salo (principal investigator)
Toboroz
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
NCT04546399· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Jill A. Salo (principal investigator)
Toboroz
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
NCT03959085· 3. fázis· Children's Oncology Group· Forrás
Contact: Jill A. Salo (principal investigator)
Fut, nem toboroz
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
NCT03914625· 3. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
NCT03067181· 3. fázis· Children's Oncology Group· Forrás
Contact: Jill A. Salo (principal investigator)
Toboroz
Project: Every Child for Younger Patients With Cancer
NCT02402244· Children's Oncology Group· Forrás
Contact: Jill A. Salo (principal investigator)
Fut, nem toboroz
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
NCT01886872· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
NCT01575548· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia
NCT00070499· 2. fázis· National Cancer Institute (NCI)· Forrás